Analysis of the cost-effectiveness of paclitaxel as alternative combination therapy for advanced ovarian cancer.

Abstract

The TP regimen's increased mean survival cost per YLG (inpatient and outpatient settings) adds a substantial benefit at an acceptable cost compared with CP therapy.